ArticlePloS one2011
Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review.Annals of the American Thoracic Society · 2014Pooled it
- Factors associated with indeterminate QuantiFERON-TB Gold Plus Test results during the COVID-19 pandemic.PloS one · 2025Article
- The new gamma interferon (IFN-γ) algorithm for tuberculosis diagnosis in cynomolgus macaques.PloS one · 2024Article
- Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers.PloS one · 2024Article
- Accuracy of interferon gamma release assays for the COVID-19 immunity assessment.Journal of virological methods · 2022Article
- Comparison of QFT-Plus and QFT-GIT tests for diagnosis ofJournal of thoracic disease · 2019Article
- Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria.Clinical microbiology reviews · 2018Review
- Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India.BMJ global health · 2018Article
- Elevated Spontaneous Interferon-γ Secretion in Human Immunodeficiency Virus-Infected Persons.Open forum infectious diseases · 2017Article
- Article
- Disseminated Mycobacterium scrofulaceum Infection in an Immunocompetent Host.Internal medicine (Tokyo, Japan) · 2017Article
- Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab.PloS one · 2017Article
- Effects of acute critical illnesses on the performance of interferon-gamma release assay.Scientific reports · 2016Article
- Cough Aerosol Cultures of Mycobacterium tuberculosis: Insights on TST / IGRA Discordance and Transmission Dynamics.PloS one · 2015Article
- High Proportion of Indeterminate QuantiFERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps.Open forum infectious diseases · 2014Article
- Variability of the QuantiFERON®-TB gold in-tube test using automated and manual methods.PloS one · 2014Article
- Implementation of an interferon-gamma release assay to screen for tuberculosis in refugees and immigrants.Journal of immigrant and minority health · 2013Article
- Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice.American journal of respiratory and critical care medicine · 2013Article
- Article
- Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigens.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInterferon gamma (IFN-γ) release assays, such as QuantiFERON®-TB Gold test (QFT-G) and QuantiFERON®-TB Gold In-Tube test (QFT-GIT) are designed to detect M. tuberculosis (Mtb) infection. Recognition of unusual IFN-γ measurements may help indicate inaccurate results.
methodsWe examined QFT-G and QFT-GIT results from subjects who had two or more tests completed. We classified unusual IFN-γ measurements as: 1) High Nil Concentration (HNC) when IFN-γ concentration in plasma from unstimulated blood exceeded 0.7 IU/mL; 2) Low Mitogen Response (LMR) when Mitogen Response was <0.5 IU/mL; 3) Very Low Mitogen Response (VLMR) when Mitogen Response was ≤-0.5 IU/mL; and 4) Very Low Antigen Response (VLAR) when the response to a Mtb antigen was ≤-0.35 IU/mL and ≤-0.5 times the IFN-γ concentration in plasma from unstimulated blood.
resultsAmong 5,309 results from 1,728 subjects, HNC occurred in 234 (4.4%) tests for 162 subjects, LMR in 108 (2.0%) tests for 85 subjects, VLMR in 22 (0.4%) tests for 21 subjects, and VLAR in 41 (0.8%) tests for 39 subjects. QFT-GIT had fewer HNC, VLMR, and VLAR (p = 0.042, 0.004, and 0.067 respectively); QFT-G had fewer LMR (p = 0.005). Twenty-four (51.6%) of 47 subjects with positive results and HNC were negative or indeterminate by all other tests. Thirteen (61.9%) of 21 subjects with positive results and LMR were negative or indeterminate by all other tests.
conclusionUnusual IFN-γ measurements including HNC, LMR, VLMR, and VLAR were encountered in small numbers, and in most instances were not seen on simultaneously or subsequently performed tests. To avoid erroneous diagnosis of Mtb infection, IGRAs with unusual IFN-γ measurements should be repeated with another blood sample and interpreted with caution if they recur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.